Myocarditis following COVID-19 mRNA vaccination.
Kanak ParmarPoemlarp MekraksakitGaspar Del Rio-PertuzPooja SethiArunee MotesMegan HughesJason WischmeyerLuis CarbajalErwin Argueta SosaPublished in: Proceedings (Baylor University. Medical Center) (2021)
Messenger RNA vaccines are the main COVID-19 vaccines authorized for use in the United States. Side effects are typically minor and transient. We report a case series of four subjects with an acute myocarditis-like illness following mRNA COVID-19 vaccination who were hospitalized at our hospital in Lubbock, Texas. Three patients were young men who presented with acute chest pain after the second dose of the mRNA-1273 vaccine. Another patient was a 53-year-old white woman who presented with acute left arm pain 3 days after the first dose of the mRNA-1273 vaccine. She was later found to have acute decompensated heart failure, and endomyocardial biopsy revealed eosinophilic injury-mediated myocarditis.
Keyphrases
- liver failure
- heart failure
- coronavirus disease
- sars cov
- respiratory failure
- drug induced
- aortic dissection
- ejection fraction
- end stage renal disease
- binding protein
- case report
- healthcare
- chronic kidney disease
- emergency department
- single cell
- ultrasound guided
- fine needle aspiration
- patient reported outcomes
- spinal cord
- acute heart failure
- acute respiratory distress syndrome